Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis

Company Overview

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $2.19 to $2.24
• 50-Day Range: $2.17 to $2.23
• 52-Week Range: $1.29 to $3.65
• Volume: 4.76 million shs
• Average Volume: 724,253 shs
• Market Capitalization: $127.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Paratek Pharmaceuticals Stock Analysis - MarketRank™

Paratek Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat, and ranked 946th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Paratek Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Paratek Pharmaceuticals is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PRTK.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Paratek Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Paratek Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 1.3 / 5
• Environmental Score: -2.98

Short Interest

There is no current short interest data available for PRTK.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added Paratek Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.00% of the stock of Paratek Pharmaceuticals is held by insiders.

Percentage Held by Institutions

53.60% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRTK Stock Analysis - Frequently Asked Questions

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its quarterly earnings data on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to analysts' expectations of $22.98 million.

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Paratek Pharmaceuticals investors own include Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), Verastem (VSTM), Citius Pharmaceuticals (CTXR), SCYNEXIS (SCYX) and Aurinia Pharmaceuticals (AUPH).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 2/01/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PRTK
• Previous Symbol: NASDAQ:TSPT
• CUSIP: 89354M10
• CIK: 1178711
• Web: www.paratekpharma.com
• Phone: (617) 807-6600
• Fax: 617-275-0039
• Employees: 268
• Year Founded: 1996

Profitability

• EPS (Most Recent Fiscal Year): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-63,570,000.00
• Net Margins: -35.44%
• Pretax Margin: -35.35%
• Return on Equity: N/A
• Return on Assets: -40.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.52
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: $160.27 million
• Price / Sales: 0.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.08) per share
• Price / Book: -0.72

Miscellaneous

• Outstanding Shares: 57,320,000
• Free Float: 52,736,000
• Market Cap: $127.82 million
• Optionable: Optionable
• Beta: 1.70